Context Capital Management’s Aspire Biopharma Warrant ASBPW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.5K | Hold |
175,000
| – | – | ﹤0.01% | 412 |
|
|
2026
Q1 | $2.9K | Hold |
175,000
| – | – | ﹤0.01% | 378 |
|
|
2025
Q4 | $2.89K | Hold |
175,000
| – | – | ﹤0.01% | 312 |
|
|
2025
Q3 | $5.23K | Hold |
175,000
| – | – | ﹤0.01% | 256 |
|
|
2025
Q2 | $7.82K | Hold |
175,000
| – | – | ﹤0.01% | 228 |
|
|
2025
Q1 | $11.8K | Hold |
175,000
| – | – | ﹤0.01% | 175 |
|
|
2024
Q4 | $8.31K | Hold |
175,000
| – | – | ﹤0.01% | 186 |
|
|
2024
Q3 | $7.4K | Buy |
+175,000
| New | +$8.33K | ﹤0.01% | 230 |
|
|
2024
Q2 | – | Sell |
-175,000
| Closed | -$5.27K | – | 239 |
|
|
2024
Q1 | $5.27K | Hold |
175,000
| – | – | ﹤0.01% | 220 |
|
|
2023
Q4 | $10.5K | Hold |
175,000
| – | – | ﹤0.01% | 179 |
|
|
2023
Q3 | $9K | Hold |
175,000
| – | – | ﹤0.01% | 214 |
|
|
2023
Q2 | $9K | Hold |
175,000
| – | – | ﹤0.01% | 217 |
|
|
2023
Q1 | $7K | Hold |
175,000
| – | – | ﹤0.01% | 282 |
|
|
2022
Q4 | $14K | Hold |
175,000
| – | – | ﹤0.01% | 302 |
|
|
2022
Q3 | $19K | Hold |
175,000
| – | – | ﹤0.01% | 422 |
|
|
2022
Q2 | $30K | Buy |
+175,000
| New | +$38.1K | ﹤0.01% | 434 |
|
Context Capital Management's ASBPW Position: Q2 2026 in Review
Context Capital Management held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2026 at 175,000 shares worth $3.5K. The position accounts for ﹤0.01% of the portfolio, ranked #412.
Context Capital Management first reported a position in ASBPW in Q2 2022 and has held it in 16 quarters since. The position peaked at $30K in Q2 2022. 2 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.
- Context Capital Management held 175,000 shares of Aspire Biopharma Warrant worth $3.5K as of Q2 2026.
- Context Capital Management left its Aspire Biopharma Warrant share count unchanged in Q2 2026.
- Aspire Biopharma Warrant made up ﹤0.01% of Context Capital Management's portfolio in Q2 2026, its #412 holding.
- Context Capital Management first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 16 quarters since.
- Context Capital Management's Aspire Biopharma Warrant position peaked at $30K in Q2 2022.
- 2 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.
Based on Context Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.